Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(194)
•••
Post by scarlet1967on Mar 31, 2021 9:18am
116 Views
Post# 32912829

Division of infectious disease

Division of infectious disease

It looks like Thera is presenting at this event on April 22, I believe they will be talking about Trogarzo.

 

Meeting ID:

JOIN BY PHONE: 1

Megan Wynn
Senior Virology Sales Specialist

phone-gray-e1598901213974.jpg

 217-741-1622

email-gray-e1598899592470.jpg

  mwynn@ITS.JNJ.com

web-gray-dark-e1598899483744.jpg

 https://www.janssen.com/us/

Symtuza

Thera-transparent.png

 

https://infectiousdiseases.wustl.edu/education/id-society-of-st-louis/id-society-of-st-louis-virtual-exhibit-hall-links-will-be-updated-visit-each-exhibitor-online-from-computer-tablet-or-smartphone-april-22-2021-600-pm-700-pm/

About division of infectious disease:

 

National Leaders in Infectious Diseases

We are involved in exceptional patient care and ground-breaking research while preparing the next generation of scientists and physicians.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities